Replimune's Second Quarter Fiscal 2027 Earnings Conference Call - REPLIMUNE GROUP INC

Financial Performance:

• No product revenue recognized in Q2 Fiscal 2027 as commercial shipments of TruDraCav began in early October (Fiscal Q3).
• Research and Development (R&D) expenses were $34.4 million, a decrease from $49.3 million in Q1, driven by the transition from pre-commercial to launch phase activities.
• Selling, General, and Administrative (SG&A) expenses increased to $21.9 million from $19.0 million in Q1, reflecting commercial team build-out, hiring, and patient support program costs.
• Net loss for the quarter was $57.1 million, an improvement from $69.8 million in Q1.
• Cash and cash equivalents ended the quarter at $307.8 million, including $141 million net proceeds from an August offering; cash on hand at June 30 was $195.3 million.
• Management expects current cash position to fund operations for greater than 12 months, covering TruDraCav launch investments and ongoing clinical trials (IGNITE3 and REVEAL).
• TruDraCav list price is $450,000 per course of therapy before rebates; dosing is lesion-volume based, requiring multiple cycles (typically 8+) and potentially generating revenue recognized over multiple quarters.

Guidance and Future Outlook:

• Explicit revenue guidance was not provided; management indicated that patient revenue recognition will be staggered over quarters due to the multi-cycle nature of treatment.
• A permanent J-code is expected to be established by April 2027 to facilitate broader adoption and reimbursement; currently utilizing a miscellaneous J-code.
• Near-term goal is to double the number of accounts initiating patient treatment by the end of the calendar year.
• Strategic priority remains penetrating the initial 200 target accounts (covering ~30% of national melanoma patients) before accelerating into the next wave of ~250 accounts (covering another ~20% of the population).
• Management aims to avoid major bottlenecks and accelerate the next wave (9-12 month target) as soon as the initial 200 accounts are fully optimized.

Business Segments and Product Lines:

• TruDraCav (RPX Platform): First commercial product; broad label allows treatment for melanoma patients progressing on PD-1-based therapy without requiring prior BRAF-targeted therapy.
• Launch Traction: Over 15 institutions have written prescriptions within the first ~20 business days; ~20 accounts have secured formulary listing; >70% engagement achieved with the initial 200 target accounts.
• Patient Support: "RepiMe and Connect Plus" patient support program is live to facilitate access.
• Pipeline: IGNITE3 (uveal melanoma) and REVEAL study (uveal melanoma) are enrolling well; Confirmatory melanoma study (I3) is open to additional sites in Europe.
• Commercial Team: Sales force is now fully staffed with 23 account management positions and a cross-functional operational excellence team; team is right-sized for launch execution.

Market and Competitive Landscape:

• Unmet Need: Addresses a critical gap for the ~10,000 addressable patients in the U.S. progressing after PD-1 therapy, where treatment options are limited; nearly 8,500 patients die of melanoma annually.
• Market Reception: Strong enthusiasm from academic and community oncologists, as well as interventional radiologists (IRs), who value the broad label and ability to treat both superficial and image-guided lesions.
• Coverage: TruDraCav rapidly listed in NCCN guidelines (Category 2a); major national and regional payers have established policies covering the label (including retreatment), representing the majority of commercially covered lives; Medicare coverage is established.
• Competition: Positioning as a rapid-response therapy with next-day delivery capabilities, contrasting with limited existing options in the PD-1 refractory setting.

Risks and Challenges:

• Operational Complexity: Workflow establishment with facilities varies by institution; challenges include securing formulary status and coordinating between oncologists and interventional radiologists.
• Supply Chain/Dosing: Revenue recognition is complex due to volume-based dosing and multi-quarter treatment courses; actual cost per patient varies significantly based on tumor burden.
• Adoption Variance: While demand is high, some institutions have slower internal processes (e.g., P&T committees) for formulary approval, though many are bypassing standard procedures due to patient urgency.
• No Guidance Risk: Absence of specific patient count or revenue guidance increases modeling uncertainty for investors.

Management Commentary and Tone:

• Tone: Highly confident, enthusiastic, and urgent; management described the launch as a "defining moment" and expressed being "surprised and pleased" by the speed of adoption.
• Confidence: Strong belief in the therapy's utility, citing real-world feedback from IRs and oncologists regarding the broad label and ease of administration.
• Strategic Focus: Emphasized three priorities: meeting patient unmet needs, ensuring supply readiness (1+ year inventory on hand), and rebuilding the commercial team.
• Communication: Clear delineation that early metrics will focus on the "funnel" (engagement, formulary access, orders) rather than specific patient counts until cohort data stabilizes.

Analyst Questions and Answers:

• Modeling Metrics (BMO Capital Markets): Management advised tracking the launch funnel (accounts on formulary vs. first scripts) rather than patient counts immediately; patient volume data will be available once cohorts complete 8+ cycles.
• Administration Timelines & Holdups (Piper Sandler): Delivery is next-day; many patients treated within days of order. No major holdups identified; delays are procedural (formulary scheduling) rather than lack of physician interest.
• Institution Readiness (Leerink Partners): Initial 200 accounts are diverse; 20+ are already treating; workflow support from operational excellence teams has been successful in 50+ site meetings.
• Sales Force Status (J.P. Morgan): Sales force is fully staffed (23 reps) and active; focus now on training, executing engagements, and expanding beyond the initial 200 accounts.
• Formulary Restrictions (Jefferies): No restrictions on volume or retreatment observed in payer policies; formularies align with label expectations (up to 24 doses in some cases).
• Patient Demographics (Kempin): Initial prescribers are predominantly high-volume academic/tertiary centers with IR capabilities, though regional centers are also adopting rapidly; physicians are utilizing therapy in both earlier and later lines of treatment.
• Superficial vs. Deep Injection Volume (Cantor): No volume data differentiation yet; deep injections (liver/lung) historically used more volume, but total volume depends on individual lesion count and size.

Other Key Points:

• Supply: Over one year of inventory is on hand produced at in-house manufacturing facilities.
• Distribution: Next-day delivery capability is a key differentiator enabling "just-in-time" treatment for patients who cannot wait.
• Label Utility: The broad label is a primary driver of adoption, allowing physicians to treat patients regardless of prior BRAF status and across various lines of PD-1 therapy.
• Clinical Data: Management reiterated that IGNITE data was representative of the real-world population; early clinical observations align with trial expectations.